surmount-1 trial tirzepatide obesity without diabetes weight loss SURMOUNT-1: Adults achieve of 16% or more at 72 weeks with Tirzepatide cuts diabetes risk by

some suggest positive effects on bone density, while others indicate no significant change or even potential risks in specific populations

Lilly continues to study the long-term effects of these medicines and works closely with healthcare professionals and people living with obesity to support their safe and appropriate use." What Happens Next The study's authors recommend that guidelines be reviewed so that patients receiving the medications are made aware of the likelihood of rapid weight regain unless the medication is sustained long-term

The broader question of how long semaglutide remains viable depends on storage conditions, reconstitution method, and handling practices

The nutritional concerns are the same across all GLP-1 receptor agonists because the underlying mechanism , reduced food intake , is shared

Other recent research has highlighted two promising non-peptide compounds, TTOAD2 and orforglipron, she said